Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer study tracks Real-World care in china

NCT ID NCT05872763

Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer (stage IIIB/IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow patients over time to see what treatments they receive, how long they live, and what genetic markers their tumors have. The goal is to understand real-world medical practice and the economic burden on patients, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

901 people

The number who actually took part.

Started

Aug 2023

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will be conducted at multiple sites that will be selected from a pool of hospitals in China from 7 geographic regions (Northwest, Northeast, North, Southwest, South, Central, East) across China. And a target number of 7-10 sites across these regions were planned to be involved to ensure a relatively even number of patients to be enrolled from each region.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cohort 1: * Participants who have diagnosed with unresectable stage IIIB/IIIC/IV NSCLC * Participants who have been diagnosed six months before the start of the study were required to have two complete tumor assessments within at least 6 months intervals after the diagnosis * Participants who were newly diagnosed within six months before the start of the study were required to have complete baseline information (see section 6.4.1) * Participants who have received standard first-line treatment defined by guideline CSCO (https://www.csco.org.cn/cn/index.aspx) and NCCN (https://www.nccn.org/) Cohort 2: * Participants who are newly diagnosed with unresectable Stage IIIB/IIIC/IV NSCLC after the start of the study * Participants who are able to be followed up by the participating site * Participants planned to receive first line anti-cancer treatment targeting unresectable stage IIIB/IIIC/IV NSCLC in the study site after study initiation Exclusion Criteria: * Participants who have received prior systematic treatment for unresectable Stage IIIB/IIIC/IV NSCLC * Participants who have participated in any anti-cancer, regimen-specified clinical study of first-line treatment for unresectable Stage IIIB/IIIC/IV NSCLC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

Contacts and locations

Locations

  • Beijing Chest Hospital

    Beijing, 101149, China

  • Cancer Hospital Chinese Academy of Medical Sciences.

    Beijing, 100021, China

  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University

    Xi'an, 710061, China

  • Guangxi Cancer Hospital of Guangxi Medical University

    Nanning, 530021, China

  • Harbin Medical University Cancer Hospital

    Harbin, 150081, China

  • Hubei Cancer Hospital

    Wuhan, 430079, China

  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

    Nanjing, 210029, China

  • Shandong Cancer Hospital

    Jinan, 250117, China

  • Shanxi Province Cancer Hospital

    Taiyuan, 030013, China

  • Sichuan Provincial Cancer Hospital

    Chengdu, 610041, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, 450052, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.